磨玻璃结节样肺腺癌的临床及遗传学特征和手术治疗效果研究
Clinical,genetic characteristics,and surgical outcomes of lung adenocarcinoma manifesting as ground-glass opacities
-
摘要: 目的 分析总结表现为肺磨玻璃结节(ground-glass opacities,GGOs)的肺腺癌患者的临床特征、手术治疗效果、基因突变结果及预后情况。方法 回顾性纳入2014年1月-2019年1月在解放军总医院海南医院胸外科行手术治疗的肺GGOs患者资料,分析其手术治疗效果、基因突变结果和预后情况。结果 共纳入165例GGOs患者,其中男性65例,女性100例,29例(17.6%)患者有吸烟史,均为男性,结节直径平均(13.63±7.16) mm,纯磨玻璃结节56例,部分实性磨玻璃结节109例。102例行电视胸腔镜肺叶切除术,单纯行肺段切除术18例,单纯行肺楔形切除术45例。清扫淋巴结站数平均(4.45±1.50)站,清扫淋巴结数目平均(11.32±7.97)个,其中15例未做淋巴结活检。术后患者均正常出院,无死亡病例,8例(4.8%)出现术后并发症,经积极处理后痊愈。术后病理提示非典型腺瘤样增生(atypical adenoma-like hyperplasia,AAH)7例(4.2%),原位腺癌(adenocarcinoma in situ,AIS)19例(11.5%),微浸润性腺癌(minimally invasive adenocarcinoma,MIA)32例(19.4%),浸润性腺癌(invasive adenocarcinoma,IPA)107例(64.8%)。侵及脏层胸膜31例,150例淋巴结清扫患者均无淋巴结转移。在70例基因检测患者中,有43例EGFR突变,KRAS突变4例。随访时间平均为(20.96±17.41)个月,107例IPA患者无随访资料,32例MIA、19例AIS和7例AAH随访均无局部复发及远处转移情况。结论 表现为GGOs的早期肺腺癌,通过肺叶切除或亚肺叶切除手术可获得良好的治疗效果,无淋巴结转移,可获得满意的远期预后。部分患者存在EGFR等基因突变,可为后期复发及转移提供靶向治疗方案。Abstract: Objective To analyze the clinical,genetic characteristics,and surgical outcomes of lung adenocarcinoma manifesting as ground-glass opacities (GGOs). Methods Patients with lung adenocarcinoma manifesting as GGOs who underwent surgery in our hospital from January 2014 to January 2019 were enrolled.Surgical outcomes,histopathology,genetic mutation status and survival data were collected. Results Among the 165 patients with GGOs,there were 65 males and 100 females.Twenty-nine (17.6%) patients had a history of smoking and they were all males.The average GGOs diameter was (13.63±7.16) mm.Among them,56 were with pure GGOs and 109 with mixed GGOs.VATS lobectomy was perfomed to 102 patients,segmentectomy to 18 patients,and wedge resection to 45 patients.The average station of lymph node dissection was (4.45±1.50),and the average number of lymph node resected was (11.32±7.97).Fifteen patients did not receive lymph node sampling.All patients were discharged from the hospital.Eight patients (4.8%) had postoperative complications and were cured after active treatment.Pathology results revealed that 7 (4.2%) cases had atypical adenoma-like hyperplasia (AAH),19 cases (11.5%) had adenocarcinoma in situ (AIS),32 cases (19.4%)had minimally invasive adenocarcinoma (MIA),and 107 cases (64.8%) had invasive adenocarcinoma (IPA).There were 31 cases with visceral pleura invasion and no lymph node metastasis was found.Of the 70 patients received genetic test,43 (61.4%) had EGFR mutations and 4 (5.7%) had KRAS mutations.The average follow-up time was (20.96±17.41) months.There was no follow-up data for 107 patients with IPA.No local recurrence and distant metastasis was observed in patients with MIA,AIS and AAH. Conclusion Greatsurgical outcomes and satisfied survival can be obtained through lobectomy or sublobectomy with or without lymph node resection for lung adenocarcinoma patients manifested as GGOs.Some patients have EGFR and other gene mutations,which may provide evidence for further targeted therapy.
下载: